Printed From:

KEVZARA—Targeting the IL-6 Receptor1

KEVZARA is a fully human monoclonal antibody that inhibits IL-6 receptor signaling.1

KEVZARA is a fully human monoclonal antibody that inhibits IL-6 receptor signaling.1

  • KEVZARA targets and binds with high affinity to soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R)2

By binding to these receptors, KEVZARA blocks inflammatory effects of IL-6 and inhibits IL-6-mediated signaling1,4

KEVZARA helps prevent disruptive effects of elevated IL-6 associated with manifestations of RA1

References: 1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc; 2017. 2. Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437. 3. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49:15-24. 4. Astrakhantseva IV, Efimov GA, Drutskaya MS, Kruglov AA, Nedospasov SA. Modern anti-cytokine therapy of autoimmune diseases. Biochemistry (Moscow). 2014;79(12):1308-1321.